Need to find a common ground with Moderna and Johnson & Johnson for initiating vaccine supply : V K Paul

Discussions are still going on with Moderna and Johnson & Johnson vaccine manufacturers to start their vaccine supplies, though the government has given Emergency Use Authorisation (EUA) for these COVID-19 vaccines, said Dr Vinod K Paul, member of NITI Aayog.

It may be noted that the foreign vaccine manufacturers including Pfizer and Moderna have been seeking indemnity against any legal issues if the vaccine may create any serious adverse reactions.

Apprising the same in a weekly press briefing on COVID-19 developments in the country, Paul informed that the option for using EUA is open for both the companies. “With regard to their import or deployment from the production of Johnson and Johnson in the country, we have been informing you that there are issues around which we still have to find a common ground with respective vaccine manufacturers and we are working in that direction.”

Commenting on the vaccine administration in children, Paul said that Zydus Cadila’s vaccine has been approved for potential use in children.

“We have information on the stock pile and our scientific bodies are discussing how and when and where to. Covaxin trial is very close to completion of trials for children. Once we have results, that vaccine will be potentially available. Biological E has also been granted permission to complete the trial,” he said.

Health Secretary, Rajesh Bhushan, Ministry of Health and Family Welfare, said, “We are still witnessing the second surge. It is not over. Public health response should be on the basis that the second surge is not over though the cases are coming down.”

He urged the public to be careful while celebrating the upcoming festivals in the wake of the pandemic.

  • Related Posts

    Donald Trump reveals 200% tariff plan for generic medicines. Will India exports be hit?

    The decision could hit India hard, as it is the largest exporter of generic drugs to the US. US President Donald Trump has announced steep tariffs on imported generic medicines,…

    IIT Kanpur scientists’ research reveals how a promising vaccine booster switches on immune cells

    Kanpur: Scientists at IIT Kanpur have revealed how an experimental molecule called EP67 switches on an important receptor found on human immune cells. EP67 is a candidate “adjuvant”, an ingredient…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Donald Trump reveals 200% tariff plan for generic medicines. Will India exports be hit?

    Donald Trump reveals 200% tariff plan for generic medicines. Will India exports be hit?

    IIT Kanpur scientists’ research reveals how a promising vaccine booster switches on immune cells

    IIT Kanpur scientists’ research reveals how a promising vaccine booster switches on immune cells

    Government takes steps to strengthen primary healthcare services

    Government takes steps to strengthen primary healthcare services

    Operation Vajra: CBN thwarts Global Syndicate, seizes 12 Crore ‘Fighter Drug’ Tablets destined for Conflict Zones

    Operation Vajra: CBN thwarts Global Syndicate, seizes 12 Crore ‘Fighter Drug’ Tablets destined for Conflict Zones

    National Health Emergency: Telangana C-section Cluster Spark Critical Alarms as Substandard Drug Suspicions spread Nationwide

    National Health Emergency: Telangana C-section Cluster Spark Critical Alarms as Substandard Drug Suspicions spread Nationwide

    Star Bio Pharma Global strengthens its position in the global nutraceutical supply Chain

    Star Bio Pharma Global strengthens its position in the global nutraceutical supply Chain